Molecular Characterization of Response and Loss of Response

The molecular characterization of response and loss of response to look sweet to me. Why? Because if we have these driver mutations, JAC2 mutation, calvertical limitation,. That's a third-wire nipple mutation that covers 90% of the patients in terms of being reason for hyperactivity of JAC2. There may be other clones that are genetically different. And how can we predict who is going to lose the response sooner rather than later? Some responds to some degree, but some respond for six months and some for three and a half years. If you have advanced patients with an anemia, anemia quality, Ruxolitum cannot be given well because it's causing more of